BEAT
HeartBeamBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
The bull case is that the April financing buys enough time for HeartBeam to turn FDA clearance, the ClearCardio launch, and the ALIGN-ACS / Mount Sinai programs into credible commercial and clinical momentum [#8-K-2026-04-16] [#10-K-2026-03-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional capital raises may still be needed despite the April 2026 offering.
Momentum
100
Value
36
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.60 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.38
Why
Momentum100 · Δ7d -
Value36 · Δ7d -0.0
Sentiment47 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
47
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 99.9 / Value 36.4 / Sentiment 46.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$48.62M
Beta
-0.79
Shares Out
34.44M
P/E (TTM) · Derived
-1.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.87
Rev YoY
-
EPS YoY
+17.9%
Gross Margin
-
Op Margin
-
Net Debt
-$2.38M
Current Ratio
0.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology